Lilly 1Q Revenues: $5.7 billion (+9%) 1Q Earnings: $1.2 billion (loss of $110.8 million 1Q17)   Comments: New pharmaceutical products, including Trulicity, Cyramza, Basaglar, Jardiance, Taltz, Lartruvo, Olumiant, and Verzenio, represented 25% of total revenue and drove 11% volume growth. These products help offset declines in established brands including Cialis, down 7% to $495.4 million, Forteo, down 10% to $313.2 million, Cymbalta and Erbitux, both down 3% to $169.6 million and $149.6 milli...